RegulatoryDEA files post-hearing brief recommending marijuana be moved to Schedule IIIRegulatoryGermany's medical cannabis insurance reform descends into regulatory disputeStudyPhase 3 trial of full-spectrum cannabis extract VER-01 for chronic low back pain published in Nature MedicineStudyUniversity of Sydney trial: cannabidiol significantly reduces chronic pain in people with nerve damageRegulatoryTGA responds to medicinal cannabis review, signalling overhaul of Australian access pathwaysBusinessFDA grants Breakthrough Therapy Designation to plant-derived cannabis extract for pain treatmentBusinessTilray expands cultivation capacity and updates guidance on German medical cannabis marketBusinessDunbar Pharma launches first plant-derived dronabinol in UK through IPS PharmaStudyAnanda Pharma's ENDOCAN study explores pharmaceutical-grade CBD for endometriosis careRegulatoryCongressional researchers note FDA has missed deadline to publish hemp cannabinoid lists and container guidanceRegulatoryDEA files post-hearing brief recommending marijuana be moved to Schedule IIIRegulatoryGermany's medical cannabis insurance reform descends into regulatory disputeStudyPhase 3 trial of full-spectrum cannabis extract VER-01 for chronic low back pain published in Nature MedicineStudyUniversity of Sydney trial: cannabidiol significantly reduces chronic pain in people with nerve damageRegulatoryTGA responds to medicinal cannabis review, signalling overhaul of Australian access pathwaysBusinessFDA grants Breakthrough Therapy Designation to plant-derived cannabis extract for pain treatmentBusinessTilray expands cultivation capacity and updates guidance on German medical cannabis marketBusinessDunbar Pharma launches first plant-derived dronabinol in UK through IPS PharmaStudyAnanda Pharma's ENDOCAN study explores pharmaceutical-grade CBD for endometriosis careRegulatoryCongressional researchers note FDA has missed deadline to publish hemp cannabinoid lists and container guidance
Institute for Cannabinoid Therapy emblem
Institute for Cannabinoid Therapy
Est. International Education
Courses
Course

Cannabis and Women's Health

An evidence-led course on the endocannabinoid system in female physiology and the role of cannabinoid therapeutics across the reproductive lifecycle.

Duration
Multi-module · self-paced
Instructor
To be announced
Level
Course
Enrolment
To be announced
Overview

This course is designed for healthcare professionals seeking a rigorous, evidence-based understanding of cannabis and women's health. It combines contemporary science, clinical reasoning and international regulatory perspective.

Learning objectives
  • Outline the role of the endocannabinoid system in female reproductive physiology and hormonal regulation.
  • Appraise the evidence for cannabinoids in menstruation-related disorders, endometriosis and menopause.
  • Evaluate safety considerations across pregnancy, lactation and fertility.
Curriculum
  1. 01
    The ECS in female physiology

    Endocannabinoid tone, ovarian cycling and hormonal cross-talk.

  2. 02
    Menstruation, endometriosis and pelvic pain

    Mechanistic rationale and appraisal of clinical evidence.

  3. 03
    Menopause and beyond

    Mood, sleep and bone health in the menopausal transition.

  4. 04
    Safety, pregnancy and lactation

    Risk appraisal and responsible patient counselling.

Who should attend
Medical practitionersNurse practitionersPharmacistsAllied healthResearchersGynaecologists
Frequently asked questions
When is this available?+

Cannabis and Women's Health is in development — coming soon. Register your interest to be notified at launch.